N-terminal brain natriuretic peptide as a screening tool for heart failure in the pacemaker population

European Heart Journal

Volumn 27, Issue 4, 2006, Pages 447-453

  Thackray, Simon D R ^a   Witte, Klaus ^a   Ghosh, Justin ^a   Nikitin, Nikolay ^a   Anderson, Anne ^a   Rigby, Alan ^a   Goode, Kevin ^a   Clark, Andrew L ^a   Cleland, John G F ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Heart failure; NT BNP; Pacemaker; Screening

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL HEART PACEMAKER; BLOOD SAMPLING; COMORBIDITY; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL EXAMINATION; PRIORITY JOURNAL; SCREENING; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIAC PACING, ARTIFICIAL; ECHOCARDIOGRAPHY; FALSE POSITIVE REACTIONS; HEART FAILURE, CONGESTIVE; HUMANS; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RISK FACTORS; ROC CURVE;

EID: 32144449405     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi657     Document Type: Article

References (37)

1. Bernstein AD, Personnet V. Survey of cardiac pacing in the United States in 1993. Am J Cardiol 1996;78:187-196.
2. Mond HG. The world survey of cardiac pacing and defibrillation:1997-Asia Pacific, Middle East, South America. Pacing Clin Electrophysiol 2001;24:856-862.
3. British Pacing and Electrophysiology Group, National Pacing Database. http://ccad3.biomed.gla.ac.uk/bpeg/
4. Lamas GA, Lee K, Sweeney M, Leon A, Yee R, Ellenbogen K, Greer S, Wilber D, Silverman R, Marinchak R, Bernstein R, Mittleman RS, Lieberman EH, Sullivan C, Zorn L, Flaker G, Schron E, Orav EJ, Goldman L. The mode selection trial (MOST) in sinus node dysfunction: design, rationale, and baseline characteristics of the first 1000 patients. Am Heart J 2000;140:541-551.
5. Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gillis AM, Sami MH, Talajic M, Tang AS, Klein GJ, Lau C, Newman DM. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med;342:1385-1391.
6. Skanes AC, Krahn AD, Yee R, Klein GJ, Connolly SJ, Kerr CR, Gent M, Thorpe KE, Roberts RS; Canadian Trial of Physiologic Pacing. Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. CTOPP Investigators. J Am Coll Cardiol 2001;38:167-172.
7. Tang AS, Roberts RS, Kerr C, Gillis AM, Green MS, Talajic M, Yusuf S, Abdollah H, Gent M, Connolly SJ. Relationship between pacemaker dependency and the effect of pacing mode on cardiovascular outcomes. Circulation 2001;103:3081-3085.
8. Rosenqvist M, Brandt J, Schuller H. Long-term pacing in sinus node disease: effects of stimulation mode on cardiovascular morbidity and mortality. Am Heart J 1988;116:16-22.
9. Sgarbossa EB, Pinski SL, Maloney JD. The role of pacing modality in determining long-term survival in the sick sinus syndrome. Ann Intern Med 1993;119:359-365.
10. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, Kutalek SP, Sharma A. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002;288:3115-3123.
11. Nielsen JC, Bottcher M, Nielsen TT, Pedersen AK, Andersen HR. Regional myocardial blood flow in patients with sick sinus syndrome randomized to long-term single chamber atrial or dual chamber pacing-effect of pacing mode and rate. J Am Coll Cardiol 2000;35:1453-1461.
12. Lee MA, Dae MW, Langberg JJ, Griffin JC, Chin MC, Finkbeiner WE, O'Connell JW, Botvinick E, Scheinman MM, Rosenqvist M. Effects of long-term right ventricular apical pacing on left ventricular perfusion, innervation, function and histology. J Am Coll Cardiol 1994;24:225-232.
13. Pyatt JR, Somauroo JD, Jackson M, Grayson AD, Osula S, Aggarwal RK, Charles RG, Connelly DT. Long-term survival after permanent pacemaker implantation: analysis of predictors for increased mortality. Europace 2002;4:113-119.
14. Sulke N, Dritsas A, Bostock J, Wells A, Morris R, Sowton E. Subclinical pacemaker syndrome: a randomised study of symptom free patients with VVI pacemakers up-graded to dual chamber devices. Br Heart J 1992;67:57-64.
15. Lukl J, Doupal V, Sovova E, Lubena L. Incidence and significance of chronotropic incompetence in patients with indications for primary pacemaker implantation or pacemaker replacement. Pacing Clin Electrophysiol 1999;22:1284-1291.
16. Israel CW, Hohnloser SH. Current status of dual-sensor pacemaker systems for correction of chronotropic incompetence. Am J Cardiol 2000;86(Suppl. 1):K86-K94.
17. Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study. BMJ 2000;321:215-218.
18. Cowie et al. Value of natriuretic peptides in the assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1347-1351.
19. Yoshimura M et al. Different secretion patterns of ANP and NT PRO-BNP in patients with congestive heart failure. Circulation 1993;87:464-469.
20. Wakakura M. Radionuclide study of left ventricular function and regional myocardial perfusion in patients with a DDD pacemaker. Kaku Igaku 1992;29:561-572.
21. Nielsen JC, Andersen HR, Thomsen PE, Thuesen L, Mortensen PT, Vesterlund T, Pedersen AK. Heart failure and echocardiographic changes during long-term follow-up of patients with sick sinus syndrome randomized to single-chamber atrial or ventricular pacing. Circulation 1998;97:987-995.
22. Paxinos G, Katritsis D, Kakouros S, Toutouzas P, Camm AJ. Long-term effect of VVI pacing on atrial and ventricular function in patients with sick sinus syndrome. Pacing Clin Electrophysiol 1998;21:728-734.
23. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
24. ISFC/WHO Task Force on Standardization of Clinical Nomenclature and Criteria for Diagnosis of lschaemic Heart Disease. Circulation 1979;59:607-609.
25. Mueller T et al. Clin Chem 2003;49:976-979.
26. Henry WL, DeMaria A, Gramiak R, King DL, Kisslo JA, Popp RL, Sahn DJ, Schiller NB, Tajik A, Teichholz LE, Weyman AE. Report of the American society of echocardiography committee on nomenclature and standards in two-dimensional echocardiography. Circulation 1980;62:212-215.
27. Jaeschke R, Guyatt GH, Sackett DL for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, III: how to use an article about a diagnostic test, B: what are the results and will they help me in caring for my patients? JAMA 1994;271:703-707.
28. Youden WJ. Index for rating diagnostic tests. Cancer 2001;3:32-35.
29. Johnson W, Omland T, Hall C, Lucas C, Myking OL, Collins C, Pfeffer M, Rouleau JL, Stevenson LW. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002;39:1623-1629.
30. Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN; Valsartan Heart Failure Trial Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002;106:2454-2458.
31. Kinugawa T, Osaki S, Kato M, Ogino K, Shimoyama M, Tomikura Y, Igawa O, Hisatome I, Shigemasa C. Effects of the angiotensin-converting enzyme inhibitor alacepril on exercise capacity and neurohormonal factors in patients with mild-to-moderate heart failure. Clin Exp Pharmacol Physiol 2002;29:1060-1065.
32. Davidson NC, Naas AA, Hanson JK, Kennedy NS, Coutie WJ, Struthers AD. Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996;77:828-831.
33. Maisel AS, Koon J, Krishnaswamy P et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001;141:367-374.
34. Smith H, Pickering RM, Struthers A, Simpson I, Mant D. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study.
35. McDonagh TA, Robb SD, Murdoch DR et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
36. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995;141:680-689.
37. Swets JA, Getty DJ, Pickett RM, D'Orsi CJ, Seltzer SE, McNeil BJ. Enhancing and evaluating diagnostic accuracy. Med Decis Making 1991;11:9-18.